FDA Rubber-Stamps Merck’s Victrelis As Combination Therapy for Chronic Hepatitis C – Genetic Engineering News
|
FDA Rubber-Stamps Merck's Victrelis As Combination Therapy for Chronic Hepatitis C
Genetic Engineering News FDA approved Merck's Victrelis™ (boceprevir) drug for treating chronic hepatitis C (CHC) genotype 1. Approval covers use of the drug in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who have … |
More: continued here